SCHEMBL3533696

SCHEMBL3533696

CN1CCN(CC#Cc2cnc(N)c3c(-c4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)csc23)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.63
AURKA O14965 14/20 0.63
ABL1 P00519 14/20 0.63
LCK P06239 14/20 0.63
CSF1R P07333 14/20 0.63
MET P08581 14/20 0.63
FGFR1 P11362 14/20 0.63
FLT1 P17948 14/20 0.63
FLT3 P36888 14/20 0.63
NEK2 P51955 14/20 0.63
ROCK1 Q13464 14/20 0.63
NTRK2 Q16620 14/20 0.63
KIT P10721 12/20 0.63
MAPK9 P45984 12/20 0.63
NTRK1 P04629 12/20 0.63
PLK4 O00444 11/20 0.63
MAPK13 O15264 11/20 0.63
INSR P06213 11/20 0.63
LYN P07948 11/20 0.63
FGFR3 P22607 11/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526628 0.94 KDR (0.68) KDRAURKAABL1LCKCSF1R
SCHEMBL3528141 0.91 CSF1R (0.70) KDRAURKAABL1LCKCSF1R
SCHEMBL3532921 0.90 LCK (0.72) KDRAURKAABL1LCKCSF1R
SCHEMBL3531752 0.87 KDR (0.72) KDRAURKAABL1LCKCSF1R
SCHEMBL3614665 0.87 KDR (0.69) KDRAURKAABL1LCKCSF1R
SCHEMBL3535176 0.87 KDR (0.69) KDRAURKAABL1LCKCSF1R
SCHEMBL3531535 0.86 KDR (0.79) KDRAURKAABL1LCKCSF1R
SCHEMBL3532623 0.86 CSF1R (0.70) KDRAURKAABL1LCKCSF1R
SCHEMBL3530645 0.85 KDR (0.73) KDRAURKAABL1LCKCSF1R
SCHEMBL3530698 0.85 CSF1R (0.67) KDRAURKAABL1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.